FFS
GSK icon

Founders Financial Securities’s GSK GSK Stock Holding History

Founders Financial Securities’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
21,673
+528
+2% +$27.9K 0.06% 284
2026
Q1 		$1.23M Buy
21,145
+605
+3% +$32.8K 0.07% 251
2025
Q4 		$1.01M Buy
20,540
+1,560
+8% +$72.8K 0.06% 280
2025
Q3 		$819K Buy
18,980
+893
+5% +$34.9K 0.06% 275
2025
Q2 		$695K Buy
18,087
+760
+4% +$29K 0.05% 288
2025
Q1 		$659K Sell
17,327
-159
-0.9% -$5.82K 0.06% 277
2024
Q4 		$591K Buy
17,486
+513
+3% +$18.5K 0.05% 267
2024
Q3 		$694K Sell
16,973
-787
-4% -$32.2K 0.06% 223
2024
Q2 		$684K Buy
17,760
+542
+3% +$22.8K 0.06% 233
2024
Q1 		$738K Buy
+17,218
New +$710K 0.08% 206
2020
Q4 		– Sell
-11,370
Closed -$535K – 233
2020
Q3 		$535K Sell
11,370
-1,544
-12% -$77.4K 0.17% 88
2020
Q2 		$658K Buy
12,914
+891
+7% +$45.7K 0.21% 83
2020
Q1 		$569K Sell
12,023
-288
-2% -$15.4K 0.21% 66
2019
Q4 		$723K Buy
12,311
+38
+0.3% +$2.11K 0.24% 64
2019
Q3 		$655K Buy
12,273
+739
+6% +$38K 0.21% 78
2019
Q2 		$577K Sell
11,534
-2,064
-15% -$104K 0.19% 75
2019
Q1 		$710K Sell
13,598
-287
-2% -$14.3K 0.23% 72
2018
Q4 		$663K Sell
13,885
-665
-5% -$32.8K 0.24% 64
2018
Q3 		$731K Sell
14,550
-18
-0.1% -$915 0.2% 70
2018
Q2 		$734K Sell
14,568
-267
-2% -$13.4K 0.23% 62
2018
Q1 		$725K Buy
14,835
+292
+2% +$13.6K 0.23% 62
2017
Q4 		$645K Buy
+14,543
New +$672K 0.21% 69
2017
Q1 		– Sell
-13,954
Closed -$672K – 103
2016
Q4 		$672K Sell
13,954
-16
-0.1% -$790 0.28% 45
2016
Q3 		$753K Sell
13,970
-54,374
-80% -$2.98M 0.32% 47
2016
Q2 		$3.7M Sell
68,344
-382
-0.6% -$20.1K 1.7% 19
2016
Q1 		$3.48M Buy
+68,726
New +$3.42M 1.64% 18
2014
Q2 		– Sell
-25,339
Closed -$1.69M – 79
2014
Q1 		$1.69M Buy
25,339
+4,679
+23% +$316K 1.13% 24
2013
Q4 		$1.38M Buy
+20,660
New +$1.34M 1.16% 18

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Founders Financial Securities's GSK Position: Q2 2026 in Review

Founders Financial Securities increased its GSK (GSK) stake by 2.5% in Q2 2026, buying an estimated $27.9K and bringing the position to 21,673 shares worth $1.14M. The position accounts for 0.06% of the portfolio, ranked #284.

Founders Financial Securities first reported a position in GSK in Q4 2013 and has held it in 28 quarters since. The position peaked at $3.7M in Q2 2016. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Founders Financial Securities held 21,673 shares of GSK worth $1.14M as of Q2 2026.
  • Founders Financial Securities bought 528 GSK shares in Q2 2026, an estimated $27.9K.
  • GSK made up 0.06% of Founders Financial Securities's portfolio in Q2 2026, its #284 holding.
  • Founders Financial Securities first reported a position in GSK in Q4 2013 and has held it in 28 quarters since.
  • Founders Financial Securities's GSK position peaked at $3.7M in Q2 2016.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Founders Financial Securities's 13F filing for Q2 2026, filed 31 Jul 2026.